NASDAQ:SLS

SELLAS Life Sciences Group (SLS) Stock Price, News & Analysis

$1.54
0.00 (0.00%)
(As of 04/22/2024 ET)
Today's Range
$1.50
$1.62
50-Day Range
$0.70
$1.55
52-Week Range
$0.50
$1.91
Volume
1.50 million shs
Average Volume
1.59 million shs
Market Capitalization
$86.66 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

SELLAS Life Sciences Group MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
94.8% Upside
$3.00 Price Target
Short Interest
Bearish
9.37% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.74 out of 5 stars

Medical Sector

831st out of 910 stocks

Pharmaceutical Preparations Industry

386th out of 421 stocks

SLS stock logo

About SELLAS Life Sciences Group Stock (NASDAQ:SLS)

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

SLS Stock Price History

SLS Stock News Headlines

The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
SELLAS Life Sciences Group Inc.
The Hard Truth About Investing For Retirement
Here’s the cold, hard truth about investing: The more capital you have, the more risk averse you can afford to be. But when you’re staring down the barrel of retirement and you’ve only got 5, 10, 50 or $100,000 saved, you’ve got to be more aggressive. In an exclusive online training, the Market expert Steven Place is revealing a powerful “roadmap” that’s leading everyday investors to easy, triple-digit wins, even if they don’t have a lot of experience in trading.
Aadi Bioscience Q4 2023 Earnings Preview
Sellas Life Sciences Group Inc (SLS)
SLS Mar 2024 4.000 put
SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group Inc
SLS Feb 2024 0.500 call
See More Headlines
Receive SLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SELLAS Life Sciences Group and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
4/22/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SLS
Employees
17
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+94.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-37,340,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1 million
Book Value
($0.25) per share

Miscellaneous

Free Float
55,368,000
Market Cap
$86.65 million
Optionable
Not Optionable
Beta
2.35
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Dr. Angelos M. Stergiou M.D. (Age 48)
    ScD h.c., Founder, President, CEO & Director
    Comp: $921.99k
  • Mr. John Thomas Burns CPA (Age 39)
    Senior VP & CFO
    Comp: $338.45k
  • Ms. Stacy E. Yeung
    VP, Associate General Counsel & Head of Compliance
  • Dr. Dragan Cicic M.D. (Age 61)
    MBA, Senior Vice President of Clinical Development
    Comp: $466.43k
  • Mr. Andrew Elnatan
    VP and Head of Regulatory Affairs, Chemistry, Manufacturing and Controls & Quality

SLS Stock Analysis - Frequently Asked Questions

Should I buy or sell SELLAS Life Sciences Group stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SELLAS Life Sciences Group in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" SLS shares.
View SLS analyst ratings
or view top-rated stocks.

What is SELLAS Life Sciences Group's stock price target for 2024?

1 brokers have issued 12-month price targets for SELLAS Life Sciences Group's shares. Their SLS share price targets range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 94.8% from the stock's current price.
View analysts price targets for SLS
or view top-rated stocks among Wall Street analysts.

How have SLS shares performed in 2024?

SELLAS Life Sciences Group's stock was trading at $1.06 at the start of the year. Since then, SLS shares have increased by 45.3% and is now trading at $1.54.
View the best growth stocks for 2024 here
.

When is SELLAS Life Sciences Group's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our SLS earnings forecast
.

How were SELLAS Life Sciences Group's earnings last quarter?

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) posted its quarterly earnings data on Thursday, March, 28th. The company reported ($0.25) earnings per share (EPS) for the quarter.

What ETFs hold SELLAS Life Sciences Group's stock?

ETFs with the largest weight of SELLAS Life Sciences Group (NASDAQ:SLS) stock in their portfolio include Sprott Junior Copper Miners ETF (COPJ).Global X Copper Miners ETF (COPX).

When did SELLAS Life Sciences Group's stock split?

SELLAS Life Sciences Group's stock reverse split on the morning of Friday, November 8th 2019. The 1-50 reverse split was announced on Wednesday, November 6th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 7th 2019. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

How do I buy shares of SELLAS Life Sciences Group?

Shares of SLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLS) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners